Search

Your search keyword '"Eurocord, Cellular Therapy ' showing total 2 results
Start Over Author "Eurocord, Cellular Therapy Topic 030215 immunology
2 results on '"Eurocord, Cellular Therapy '

1. Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation

Author

Cunha, Renato, Zago, Marco A, Querol, Sergio, Volt, Fernanda, Ruggeri, Annalisa, Sanz, Guillermo, Pouthier, Fabienne, Kogler, Gesine, Vicario, José L, Bergamaschi, Paola, Saccardi, Riccardo, Lamas, Carmen H, Díaz-de-Heredia, Cristina, Michel, Gerard, Bittencourt, Henrique, Tavella, Marli, Panepucci, Rodrigo A, Fernandes, Francisco, Pavan, Julia, Gluckman, Eliane, Rocha, Vanderson, and Eurocord, Cord Blood Committee Cellular Therapy–Immunobiology Working Party of the European Society for Blood and Marrow Transplantation, Netcord and Faculdade de Medicina de Ribeirão Preto–Faculdade de Medicina de São Paulo, Universidade de São Paulo

Subjects
TIRAP, Male, Transplantation Conditioning, Gene Expression, Biochemistry, HEMATOLOGIC MALIGNANCIES, 0302 clinical medicine, HLA Antigens, VERSUS-HOST-DISEASE, Genotype, Protein Isoforms, CTLA-4 Antigen, Child, Immune response gene, Histocompatibility Testing, Hematology, BIOESTATÍSTICA, Middle Aged, Fetal Blood, TNF-ALPHA, 030220 oncology & carcinogenesis, Cord blood, Child, Preschool, Hematologic Neoplasms, Female, Cord Blood Stem Cell Transplantation, Unrelated Donors, CLINICAL-TRIALS, Adult, Adolescent, Immunology, NLR Proteins, Human leukocyte antigen, Biology, Disease-Free Survival, 03 medical and health sciences, Immune system, Humans, Alleles, Adaptor Proteins, Signal Transducing, Proportional Hazards Models, Retrospective Studies, Polymorphism, Genetic, Umbilical Cord Blood Transplantation, Infant, STEM-CELL TRANSPLANTATION, Cell Biology, CONSENSUS DEVELOPMENT PROJECT, Myeloablative Agonists, BONE-MARROW-TRANSPLANTATION, Transplantation, IDENTICAL SIBLING DONORS, WORKING GROUP-REPORT, Apoptosis Regulatory Proteins, 030215 immunology
Abstract

We evaluated the impact of recipient and cord blood unit (CBU) genetic polymorphisms related to immune response on outcomes after unrelated cord blood transplantations (CBTs). Pretransplant DNA samples from 696 CBUs with malignant diseases were genotyped for NLRP1, NLRP2, NLRP3, TIRAP/Mal, IL10, REL, TNFRSF1B, andCTLA4. HLA compatibility was 6 of 6 in 10%, 5 of 6 in 39%, and >= 4 of 6 in 51% of transplants. Myeloablative conditioning was used in 80%, and in vivo T-cell depletion in 81%, of cases. The median number of total nucleated cells infused was 3.4 x 10(7)/kg. In multivariable analysis, patients receiving CBUs with GG-CTLA4 genotype had poorer neutrophil recovery (hazard ratio [HR], 1.33; P = .02), increased nonrelapse mortality (NRM) (HR, 1.50; P

Published
2017

2. A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome

Author

Shekhovtsova, Zhanna, Bonfim, Carmem M., Ruggeri, Annalisa, Nichele, Samantha, Page, Kristin M., Alseraihy, Amal, Barriga, Francisco, de Toledo Codina, José Sánchez, Veys, Paul, Boelens, Jaap Jan, Mellgren, Karin, Bittencourt, Henrique, O’Brien, Tracey, Shaw, Peter J., Chybicka, Alicja, Volt, Fernanda, Giannotti, Federica, Gluckman, Eliane, Kurtzberg, Joanne, Gennery, Andrew R., Rocha, Vanderson, and Eurocord, Cord Blood Committee of Cellular Therapy and Immunobiology Working Party of the EBMT, Federal University of Parana, Duke University Medical Center and Inborn Errors Working Party of the EBMT

Subjects
Male, medicine.medical_specialty, Wiskott–Aldrich syndrome, Graft vs Host Disease, Cord Blood Stem Cell Transplantation, macromolecular substances, Umbilical cord, Gastroenterology, Risk Assessment, Article, 03 medical and health sciences, 0302 clinical medicine, Cell Therapy & Immunotherapy, Internal medicine, hemic and lymphatic diseases, medicine, Journal Article, Humans, Cumulative incidence, Risk factor, Child, Hematology, business.industry, Umbilical Cord Blood Transplantation, Infant, Newborn, Infant, medicine.disease, Surgery, Wiskott-Aldrich Syndrome, Transplantation, medicine.anatomical_structure, Treatment Outcome, 030220 oncology & carcinogenesis, Child, Preschool, Female, business, Unrelated Donors, 030215 immunology
Abstract

Wiskott-Aldrich syndrome is a severe X-linked recessive immune deficiency disorder. A scoring system of Wiskott-Aldrich syndrome severity (0.5-5) distinguishes two phenotypes: X-linked thrombocytopenia and classic Wiskott-Aldrich syndrome. Hematopoietic cell transplantation is curative for Wiskott-Aldrich syndrome; however, the use of unrelated umbilical cord blood transplantation has seldom been described. We analyzed umbilical cord blood transplantation outcomes for 90 patients. The median age at umbilical cord blood transplantation was 1.5 years. Patients were classified according to clinical scores [2 (23%), 3 (30%), 4 (23%) and 5 (19%)]. Most patients underwent HLA-mismatched umbilical cord blood transplantation and myeloablative conditioning with anti-thymocyte globulin. The cumulative incidence of neutrophil recovery at day 60 was 89% and that of grade II-IV acute graft-versus-host disease at day 100 was 38%. The use of methotrexate for graft-versus-host disease prophylaxis delayed engraftment (P=0.02), but decreased acute graft-versus-host disease (P=0.03). At 5 years, overall survival and event-free survival rates were 75% and 70%, respectively. The estimated 5-year event-free survival rates were 83%, 73% and 55% for patients with a clinical score of 2, 4-5 and 3, respectively. In multivariate analysis, age

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results